Skip to main content
. 2020 Dec 15;11:615972. doi: 10.3389/fphar.2020.615972

FIGURE 5.

FIGURE 5

Pooled odds ratio and forest plot of secondary infections between the anti-IL-6 signaling treatment group and standard of care group in patients with COVID-19. Twelve studies were included in the statistical analysis on secondary infections, including 639 patients treated with IL-6 signaling inhibitors and 985 patients with SOC. There was no significant difference in terms of secondary infection rates between patients with COVID-19 treated with anti-IL-6 signaling agents and those treated with SOC (pooled OR = 1.21, 95% CI 0.70–2.08, p = 0.50).